



**Procter & Gamble Hygiene  
and Health Care Limited**  
CIN: L24239MH1964PLC012971  
Registered Office:  
P&G Plaza  
Cardinal Gracias Road, Chakala  
Andheri (E), Mumbai - 400099  
Tel: (91-22) 6958 6000  
Fax: (91-22) 6958 7337  
Website: in.pg.com

August 28, 2024

To,  
The Corporate Relations Department  
The BSE Limited  
Department of Corporate Services  
Phiroze Jeejeebhoy Towers,  
Dalal Street, Mumbai – 400001  
**Ref:- Scrip Code:- 500459**

To,  
The Listing Department  
The National Stock Exchange of India Limited  
Exchange Plaza, Plot No. C/1, G Block,  
Bandra Kurla Complex, Bandra (East),  
Mumbai – 400051  
**Ref:- Scrip Code:- PGHH**

Dear Sir / Madam,

**Sub: Outcome of the Board Meeting held on August 28, 2024**

We are pleased to inform you that a meeting of the Board of Directors of the Company held today (commenced at 2:48 pm and ended at 3.29 pm), the Audited Financial Results for the Financial Year ended June 30, 2024 were approved.

We are enclosing herewith the following:

- a. Audited Financial Results for the Financial Year ended June 30, 2024, as per format prescribed under Regulation 33 of Securities Exchange Board of India (Listing Obligations and Disclosure Requirements), Regulations, 2015;
- b. Auditor's Report, in respect of the aforementioned Financial Results, as furnished by the Statutory Auditors of the Company;
- c. A declaration with respect to Audit Report with unmodified opinion to the aforementioned Audited Financial Results

We are pleased to further inform you that the Board of Directors of the Company at its meeting held today, *inter alia*, have recommended a final dividend of Rs. 95 per Equity Share (Nominal Value of Rs. 10/- each), for the Financial Year ended June 30, 2024. The dividend shall be paid between November 19, 2024 to December 15, 2024, on approval of the Members at the 60<sup>th</sup> Annual General Meeting.

Kindly take the same on record. Thanking you.

For **Procter & Gamble Hygiene and Health Care Limited**

**Ghanashyam Hegde**  
Company Secretary



Procter & Gamble Hygiene  
and Health Care Limited  
CIN : L24239MH1964PLC012971  
Registered Office: P&G Plaza  
Cardinal Gracias Road, Chakala  
Andheri (E), Mumbai 400 099  
Tel: (91-22) 6958 6000  
Fax: (91-22) 6958 7337  
Website: in.pg.com

STATEMENT OF AUDITED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED 30th JUNE 2024

(₹ in Lakhs)

Particulars	(1)	(2)	(3)	(4)	(5)
	Three Months Ended 30th June 2024	Preceding Three Months Ended 31st March 2024	Corresponding Three Months Ended 30th June 2023	Year Ended 30th June 2024	Previous Year Ended 30th June 2023
	(Audited) Refer Note 12	(Unaudited)	(Audited) Refer Note 12	(Audited)	(Audited)
<b>1 Income</b>					
Sale of products	92 743	99 815	84 874	4 19 157	3 90 521
Other operating revenues	432	402	379	1 413	1 269
<b>2 Revenue from operations</b>	<b>93 175</b>	<b>1 00 217</b>	<b>85 253</b>	<b>4 20 570</b>	<b>3 91 790</b>
<b>3 Other income</b>	<b>731</b>	<b>1 359</b>	<b>1 010</b>	<b>5 225</b>	<b>4 058</b>
<b>Total income (2+3)</b>	<b>93 906</b>	<b>1 01 576</b>	<b>86 263</b>	<b>4 25 795</b>	<b>3 95 848</b>
<b>4 Expenses</b>					
a) Cost of raw and packing materials consumed	17 685	16 400	19 990	77 194	84 755
b) Purchases of stock-in-trade (Traded goods)	23 180	18 086	19 309	85 438	82 401
c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	( 2 830)	( 710)	( 3 321)	( 1 213)	( 853)
d) Employee benefits expense	6 713	6 009	4 807	24 564	20 579
e) Finance costs	( 8)	2 242	300	2 678	1 138
f) Depreciation and amortization expense	1 340	1 454	1 541	5 650	5 836
g) Impairment losses (Refer Note 7)	1 303	—	—	1 303	—
g) Advertising & sales promotion expenses	15 371	13 409	5 354	56 797	42 652
h) Other expenses	19 924	21 292	17 625	79 464	75 393
<b>Total expenses</b>	<b>82 678</b>	<b>78 182</b>	<b>65 605</b>	<b>3 31 875</b>	<b>3 11 901</b>
<b>5 Profit before tax (2+3-4)</b>	<b>11 228</b>	<b>23 394</b>	<b>20 658</b>	<b>93 920</b>	<b>83 947</b>
<b>6 Tax expense</b>					
a) Current tax	3 292	6 967	5 448	25 955	23 052
b) Deferred tax	( 167)	( 820)	86	( 1 586)	( 1 208)
c) Prior year tax adjustments	( 3)	1 810	—	2 049	( 5 711)
<b>7 Profit for the period (5-6)</b>	<b>8 106</b>	<b>15 437</b>	<b>15 124</b>	<b>67 502</b>	<b>67 814</b>
<b>8 Other comprehensive income</b>					
Items that will not be reclassified to profit or loss:					
Remeasurement of the defined benefit plans	( 186)	429	( 989)	738	( 999)
Income tax effect on above	47	( 108)	246	( 186)	251
<b>Total other comprehensive income for the period</b>	<b>( 139)</b>	<b>321</b>	<b>( 741)</b>	<b>552</b>	<b>( 748)</b>
<b>9 Total comprehensive income for the period (7+8)</b>	<b>7 967</b>	<b>15 758</b>	<b>14 383</b>	<b>68 054</b>	<b>67 066</b>
<b>10 Paid-up equity share capital (Face Value ₹ 10 per equity share)</b>	<b>3 246</b>	<b>3 246</b>	<b>3 246</b>	<b>3 246</b>	<b>3 246</b>
<b>11 Other Equity</b>				<b>74 240</b>	<b>91 357</b>
<b>12 Earnings per Share (Face value of ₹ 10 per equity share) (not annualised) :</b>					
a) Basic	24.97	47.56	46.59	207.95	208.91
b) Diluted	24.97	47.56	46.59	207.95	208.91

See accompanying notes to the financial results

Notes:

## 1 Statement of Assets and Liabilities

(₹ in Lakhs)

Particulars	As at	As at
	30 <sup>th</sup> June 2024 (Audited)	30 <sup>th</sup> June 2023 (Audited)
<b>ASSETS</b>		
<b>Non-current assets</b>		
Property, plant and equipment	13 916	17 004
Capital work-in-progress	2 775	2 276
<b>Financial assets</b>		
(i) Loans	3 146	2 737
(ii) Other financial assets	955	909
Deferred tax assets (Net)	7 487	6 554
Non-current tax assets (Net)	25 919	24 622
Other non-current assets	11 690	10 060
<b>Total non-current assets</b>	<b>65 888</b>	<b>64 162</b>
<b>Current assets</b>		
Inventories	22 556	21 980
<b>Financial assets</b>		
(i) Trade receivables	24 083	21 628
(ii) Cash and cash equivalents	57 367	96 383
(iii) Bank balances other than (ii) above	1 453	1 416
(iv) Loans	389	369
(v) Other financial assets	8 924	3 277
Other current assets	5 196	4 517
	<b>1 19 968</b>	<b>1 49 570</b>
Non current assets held for sale	---	---
<b>Total current assets</b>	<b>1 19 968</b>	<b>1 49 570</b>
<b>Total Assets</b>	<b>1 85 856</b>	<b>2 13 732</b>
<b>EQUITY AND LIABILITIES</b>		
<b>EQUITY</b>		
Equity share capital	3 246	3 246
Other equity	74 240	91 357
<b>Total Equity</b>	<b>77 486</b>	<b>94 603</b>
<b>LIABILITIES</b>		
<b>Non-current liabilities</b>		
<b>Financial liabilities</b>		
(i) Lease liabilities	1	84
Provisions	10 303	10 542
<b>Total non-current liabilities</b>	<b>10 304</b>	<b>10 626</b>
<b>Current liabilities</b>		
<b>Financial liabilities</b>		
(i) Lease liabilities	307	319
(ii) Trade payables		
Total outstanding dues of micro enterprises and small enterprises	717	1 946
Total outstanding dues of creditors other than micro enterprises and small enterprises	84 448	95 161
(iii) Other financial liabilities	3 165	2 538
Other current liabilities	4 791	4 934
Provisions	1 055	1 035
Current tax liabilities (net)	3 583	2 570
<b>Total current liabilities</b>	<b>98 066</b>	<b>1 08 503</b>
<b>Total Liabilities</b>	<b>1 08 370</b>	<b>1 19 129</b>
<b>Total Equity and Liabilities</b>	<b>1 85 856</b>	<b>2 13 732</b>

2 Statement of Cash Flows

(₹ in Lakhs)

Particulars	Year Ended	Year Ended
	30 <sup>th</sup> June 2024 (Audited)	30 <sup>th</sup> June 2023 (Audited)
<b>A. Cash Flows from Operating Activities</b>		
Profit before tax	93 920	83 947
<b>Adjustments for:</b>		
Depreciation and amortization expense	5 650	5 836
Loss on disposal of property, plant and equipment	554	83
Finance costs	734	1 138
Allowance for doubtful receivables (Net of recovery)	99	109
Interest income	( 4 399)	( 3 508)
Impairment losses	1 303	---
Net foreign exchange (gain)	158	38
Inventory written off (net of Insurance claims recovered)	1 261	896
Provisions no longer required written back	( 694)	( 408)
Expense recognised in respect of equity settled share based payments	850	848
<b>Operating profit before working capital changes</b>	<b>99 436</b>	<b>88 979</b>
<b>Working capital adjustments</b>		
(Increase) in trade and other receivables	( 2 554)	( 2 511)
(Increase) / Decrease in financial assets	( 6 156)	( 866)
(Increase) / Decrease in inventories	( 1 837)	526
(Increase) in other assets	( 2 309)	( 2 029)
(Decrease) / Increase in trade and other payables	( 11 549)	20 695
(Decrease) / Increase in provisions	( 156)	737
<b>Cash generated from operations</b>	<b>74 875</b>	<b>1 05 531</b>
Income taxes paid	( 27 822)	( 22 954)
<b>Net cash generated from operating activities</b>	<b>47 053</b>	<b>82 577</b>
<b>B. Cash Flows from Investing Activities</b>		
Loan given to related parties	( 70 000)	---
Loan repaid by related parties	70 000	---
Interest received	4 433	3 451
Payment to acquire property, plant and equipment	( 4 468)	( 4 444)
Proceeds from sale of property, plant and equipment	141	2
Changes in earmarked balances	---	---
<b>Net cash generated (used in) investing activities</b>	<b>106</b>	<b>( 991)</b>
<b>C. Cash Flows from Financing Activities</b>		
Dividend paid	( 86 021)	( 47 068)
Principal payment of lease liabilities	( 95)	( 107)
Interest paid on lease liabilities	( 8)	( 12)
Interest paid other than on lease liabilities	( 51)	( 514)
<b>Net cash (used in) financing activities</b>	<b>( 86 175)</b>	<b>( 47 701)</b>
<b>Net (decrease) / increase in cash and cash equivalents</b>	<b>( 39 017)</b>	<b>33 885</b>
Cash and cash equivalents at the beginning of the year	96 383	62 498
Effect of exchange differences on translation of foreign currency cash and cash equivalents	---	7
<b>Cash and cash equivalents at the end of the period / year</b>	<b>57 367</b>	<b>96 383</b>

- 3 The above audited financial results for the quarter and year ended June 30, 2024, have been reviewed and recommended by the Audit Committee, and approved by the Board of Directors of the Company at their respective meetings held on August 28, 2024. These financial results have been subject to an audit by the statutory auditors of the Company, who have expressed an unmodified opinion thereon. These financial results are prepared and published in accordance with Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
- 4 The Financial Results are prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standards (Ind AS), as amended, prescribed under Section 133 of the Companies Act, 2013, read with relevant Rules issued thereunder and other accounting principles generally accepted in India.
- 5 The Board of Directors at its meeting held on August 28, 2024 have recommended a payment of final dividend of ₹ 95 per equity share of face value ₹10 each aggregating to ₹ 30 838 lakhs.
- 6 The Company has arrived at an Advanced Pricing Agreement with the concerned tax authorities, determining appropriate transfer pricing methodology for certain identified transactions with the Company's affiliate(s) for the financial years 2010-11 to 2018-19. As a consequence of this agreement, an additional tax liability, amounting to ₹ 1 656 lakh, and interest amounting to ₹ 1 944 lakhs, have been accounted as Prior Period Tax Adjustments and Finance Costs respectively. In view of the above, contingent liabilities have been reduced by ₹ 8 699 lakhs.
- 7 Certain Property, Plant & Equipment of the Company having a written down value of ₹ 2 282 lakhs as at 30 June, 2024, which were licensed to a contract manufacturer whose arrangement was terminated in F.Y. 2022-23, have been tested for impairment and a loss amounting to ₹ 1303 lakhs has been recognized in the financial results for the quarter and year ended June 30, 2024.
- 8 During the preceding year, the Company had reversed tax provisions amounting to ₹ 5 844 lakhs in respect of past Income Tax Litigations pertaining to certain years, based on a favourable ruling by the Income Tax Appellate Tribunal in a similar case of the Company pertaining to an earlier year.
- 9 The Company has identified Health and Hygiene Products as its single primary reportable segment in accordance with the requirements of Ind AS 108 - Operating Segments. Accordingly, no separate segment information has been provided.
- 10 The Statement of Assets and Liabilities as at June 30, 2024, is attached therewith as Note 1.
- 11 The Statement of Cash Flows for the year ended June 30, 2024, has been prepared under the indirect method as set out in Ind AS-7 on the "Statement of Cash Flows" and is attached herewith as Note 2.
- 12 The figures of last quarter ended June 30 are the balancing figures between audited figures in respect of the full financial year and the published year to date figures up to the third quarter of the respective financial years.

For and on behalf of the Board of Directors of  
Procter & Gamble Hygiene and Health Care Limited

KUMAR  
VENKATASU  
BRAMANIAN  
Kumar Venkatasubramanian  
Managing Director

Digitally signed by KUMAR  
VENKATASUBRAMANIAN  
Date: 2024.08.28 15:10:37  
+05'30'

Place: Mumbai  
Date: 28th August 2024



**Procter & Gamble Hygiene  
and Health Care Limited**  
CIN: L24239MH1964PLC012971  
Registered Office:  
P&G Plaza  
Cardinal Gracias Road, Chakala  
Andheri (E), Mumbai - 400099  
Tel: (91-22) 6958 6000  
Fax: (91-22) 6958 7337  
Website: in.pg.com

August 28,2024

To,  
The Corporate Relations Department  
The BSE Limited  
Department of Corporate Services  
Phiroze Jeejeebhoy Towers,  
Dalal Street, Mumbai - 400001  
**Ref:- Scrip Code:- 500459**

To,  
The Listing Department  
The National Stock Exchange of India Limited  
Exchange Plaza, Plot No. C/1, G Block,  
Bandra Kurla Complex, Bandra (East),  
Mumbai - 400051  
**Ref:- Scrip Code:- PGHH**

Dear Sir/Madam,

**Sub: Declaration with respect to Audit Report with unmodified opinion to the Audited  
Financial Results for the Financial Year ended June 30, 2024**

We hereby declare that Audited Financial Results for the Financial Year ended June 30, 2024 which have been approved by the Board of Directors of the Company at meeting held today, i.e., August 28, 2024, the Statutory Auditors, Kalyaniwalla & Mistry LLP have not expressed any modified opinion(s) in their Audit Report.

The above declaration is made pursuant to Regulation 33 (3) (d) of the Securities Exchange and Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

Yours faithfully,

**For Procter & Gamble Hygiene and Health Care Limited**

**Ghanashyam Hegde**  
Company Secretary

***INDEPENDENT AUDITOR'S REPORT  
TO THE BOARD OF DIRECTORS  
PROCTER & GAMBLE HYGIENE AND HEALTH CARE LIMITED***

**Report on the Audit of the Financial Results**

**Opinion**

We have audited the accompanying annual Financial Results of **PROCTER & GAMBLE HYGIENE AND HEALTH CARE LIMITED** (“the Company”) for the year ended June 30, 2024, attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the Securities and Exchange Board of India (SEBI) (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (“LODR Regulations”), duly initialled by us for identification.

In our opinion and to the best of our information and according to the explanations given to us, these financial results:

- i) are presented in accordance with the requirements of Regulation 33 of the LODR Regulations in this regard; and
- ii) give a true and fair view in conformity with the applicable Indian Accounting Standards (“Ind AS”) and other accounting principles generally accepted in India of the net profit and other comprehensive income and other financial information of the Company for the year ended June 30, 2024.

**Basis for Opinion**

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Companies Act, 2013 (the Act). Our responsibilities under those Standards are further described in the *Auditor's Responsibilities for the Audit of the Financial Results* section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Act and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

**Board of Directors' Responsibilities for the Financial Results**

These Financial Results have been prepared on the basis of the annual financial statements. The Company's Board of Directors are responsible for the preparation and presentation of these financial results that give a true and fair view of the net profit and other comprehensive income and other financial information in accordance with the Indian Accounting Standards prescribed under Section 133 of the Act read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the LODR Regulations. The Board of Directors of the Company are responsible for maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the accuracy and completeness of the accounting

records, relevant to the preparation and presentation of the financial results that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the financial results, the Board of Directors are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors are also responsible for overseeing the Company's financial reporting process.

#### **Auditor's Responsibilities for the Audit of the Financial Results**

Our objectives are to obtain reasonable assurance about whether the financial results as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial results.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the financial results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under Section 143(3) (i) of the Act, we are also responsible for expressing our opinion on whether the Company has adequate internal financial controls with reference to financial statements in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.
- Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.

- Evaluate the overall presentation, structure and content of the financial results, including the disclosures, and whether the financial results represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

### **Other Matter**

The Financial Results include the results for the quarter ended June 30, of the respective financial years, being the balancing figures between the audited figures in respect of the full financial year and the published unaudited year to date figures up to the end of the third quarter of the relevant financial year which were subjected to limited review by us.

Our opinion on the Financial Results is not modified in respect of the above matter.

### ***For KALYANIWALLA & MISTRY LLP*** ***CHARTERED ACCOUNTANTS***

Firm Regn. No.: 104607W / W100166

ROSHNI  
RAYOMAND  
MARFATIA

Digitally signed by ROSHNI RAYOMAND MARFATIA  
DN: cn=ROSHNI RAYOMAND MARFATIA, o=KALYANIWALLA & MISTRY LLP, ou=KALYANIWALLA & MISTRY LLP, email=roshni.rayomand.marfatia@kalyaniwalla.com, c=IN  
Date: 2024.08.28 15:30:22 +05'30'

*Roshni Marfatia*  
**PARTNER**

M. No.: 106548

UDIN: 24106548BKCSWE7462

Mumbai: August 28, 2024.





Procter & Gamble Hygiene  
and Health Care Limited  
CIN : L24239MH1964PLC012971  
Registered Office: P&G Plaza  
Cardinal Gracias Road, Chakala  
Andheri (E), Mumbai 400 099  
Tel: (91-22) 6958 6000  
Fax: (91-22) 6958 7337  
Website: in.pg.com

STATEMENT OF AUDITED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED 30th JUNE 2024

(₹ in Lakhs)

Particulars	(1)	(2)	(3)	(4)	(5)
	Three Months Ended 30th June 2024	Preceding Three Months Ended 31st March 2024	Corresponding Three Months Ended 30th June 2023	Year Ended 30th June 2024	Previous Year Ended 30th June 2023
	(Audited) Refer Note 12	(Unaudited)	(Audited) Refer Note 12	(Audited)	(Audited)
<b>1 Income</b>					
Sale of products	92 743	99 815	84 874	4 19 157	3 90 521
Other operating revenues	432	402	379	1 413	1 269
<b>2 Revenue from operations</b>	<b>93 175</b>	<b>1 00 217</b>	<b>85 253</b>	<b>4 20 570</b>	<b>3 91 790</b>
<b>3 Other income</b>	<b>731</b>	<b>1 359</b>	<b>1 010</b>	<b>5 225</b>	<b>4 058</b>
<b>Total income (2+3)</b>	<b>93 906</b>	<b>1 01 576</b>	<b>86 263</b>	<b>4 25 795</b>	<b>3 95 848</b>
<b>4 Expenses</b>					
a) Cost of raw and packing materials consumed	17 685	16 400	19 990	77 194	84 755
b) Purchases of stock-in-trade (Traded goods)	23 180	18 086	19 309	85 438	82 401
c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	( 2 830)	( 710)	( 3 321)	( 1 213)	( 853)
d) Employee benefits expense	6 713	6 009	4 807	24 564	20 579
e) Finance costs	( 8)	2 242	300	2 678	1 138
f) Depreciation and amortization expense	1 340	1 454	1 541	5 650	5 836
g) Impairment losses (Refer Note 7)	1 303	—	—	1 303	—
g) Advertising & sales promotion expenses	15 371	13 409	5 354	56 797	42 652
h) Other expenses	19 924	21 292	17 625	79 464	75 393
<b>Total expenses</b>	<b>82 678</b>	<b>78 182</b>	<b>65 605</b>	<b>3 31 875</b>	<b>3 11 901</b>
<b>5 Profit before tax (2+3-4)</b>	<b>11 228</b>	<b>23 394</b>	<b>20 658</b>	<b>93 920</b>	<b>83 947</b>
<b>6 Tax expense</b>					
a) Current tax	3 292	6 967	5 448	25 955	23 052
b) Deferred tax	( 167)	( 820)	86	( 1 586)	( 1 208)
c) Prior year tax adjustments	( 3)	1 810	—	2 049	( 5 711)
<b>7 Profit for the period (5-6)</b>	<b>8 106</b>	<b>15 437</b>	<b>15 124</b>	<b>67 502</b>	<b>67 814</b>
<b>8 Other comprehensive income</b>					
Items that will not be reclassified to profit or loss:					
Remeasurement of the defined benefit plans	( 186)	429	( 989)	738	( 999)
Income tax effect on above	47	( 108)	246	( 186)	251
<b>Total other comprehensive income for the period</b>	<b>( 139)</b>	<b>321</b>	<b>( 741)</b>	<b>552</b>	<b>( 748)</b>
<b>9 Total comprehensive income for the period (7+8)</b>	<b>7 967</b>	<b>15 758</b>	<b>14 383</b>	<b>68 054</b>	<b>67 066</b>
<b>10 Paid-up equity share capital (Face Value ₹ 10 per equity share)</b>	<b>3 246</b>	<b>3 246</b>	<b>3 246</b>	<b>3 246</b>	<b>3 246</b>
<b>11 Other Equity</b>				<b>74 240</b>	<b>91 357</b>
<b>12 Earnings per Share (Face value of ₹ 10 per equity share) (not annualised) :</b>					
a) Basic	24.97	47.56	46.59	207.95	208.91
b) Diluted	24.97	47.56	46.59	207.95	208.91

See accompanying notes to the financial results

Notes:

## 1 Statement of Assets and Liabilities

(₹ in Lakhs)

Particulars	As at	As at
	30 <sup>th</sup> June 2024 (Audited)	30 <sup>th</sup> June 2023 (Audited)
<b>ASSETS</b>		
<b>Non-current assets</b>		
Property, plant and equipment	13 916	17 004
Capital work-in-progress	2 775	2 276
<b>Financial assets</b>		
(i) Loans	3 146	2 737
(ii) Other financial assets	955	909
Deferred tax assets (Net)	7 487	6 554
Non-current tax assets (Net)	25 919	24 622
Other non-current assets	11 690	10 060
<b>Total non-current assets</b>	<b>65 888</b>	<b>64 162</b>
<b>Current assets</b>		
Inventories	22 556	21 980
<b>Financial assets</b>		
(i) Trade receivables	24 083	21 628
(ii) Cash and cash equivalents	57 367	96 383
(iii) Bank balances other than (ii) above	1 453	1 416
(iv) Loans	389	369
(v) Other financial assets	8 924	3 277
Other current assets	5 196	4 517
	<b>1 19 968</b>	<b>1 49 570</b>
Non current assets held for sale	---	---
<b>Total current assets</b>	<b>1 19 968</b>	<b>1 49 570</b>
<b>Total Assets</b>	<b>1 85 856</b>	<b>2 13 732</b>
<b>EQUITY AND LIABILITIES</b>		
<b>EQUITY</b>		
Equity share capital	3 246	3 246
Other equity	74 240	91 357
<b>Total Equity</b>	<b>77 486</b>	<b>94 603</b>
<b>LIABILITIES</b>		
<b>Non-current liabilities</b>		
<b>Financial liabilities</b>		
(i) Lease liabilities	1	84
Provisions	10 303	10 542
<b>Total non-current liabilities</b>	<b>10 304</b>	<b>10 626</b>
<b>Current liabilities</b>		
<b>Financial liabilities</b>		
(i) Lease liabilities	307	319
(ii) Trade payables		
Total outstanding dues of micro enterprises and small enterprises	717	1 946
Total outstanding dues of creditors other than micro enterprises and small enterprises	84 448	95 161
(iii) Other financial liabilities	3 165	2 538
Other current liabilities	4 791	4 934
Provisions	1 055	1 035
Current tax liabilities (net)	3 583	2 570
<b>Total current liabilities</b>	<b>98 066</b>	<b>1 08 503</b>
<b>Total Liabilities</b>	<b>1 08 370</b>	<b>1 19 129</b>
<b>Total Equity and Liabilities</b>	<b>1 85 856</b>	<b>2 13 732</b>

2 Statement of Cash Flows

(₹ in Lakhs)

Particulars	Year Ended 30 <sup>th</sup> June 2024 (Audited)	Year Ended 30 <sup>th</sup> June 2023 (Audited)
<b>A. Cash Flows from Operating Activities</b>		
Profit before tax	93 920	83 947
<b>Adjustments for:</b>		
Depreciation and amortization expense	5 650	5 836
Loss on disposal of property, plant and equipment	554	83
Finance costs	734	1 138
Allowance for doubtful receivables (Net of recovery)	99	109
Interest income	( 4 399)	( 3 508)
Impairment losses	1 303	---
Net foreign exchange (gain)	158	38
Inventory written off (net of Insurance claims recovered)	1 261	896
Provisions no longer required written back	( 694)	( 408)
Expense recognised in respect of equity settled share based payments	850	848
<b>Operating profit before working capital changes</b>	<b>99 436</b>	<b>88 979</b>
<b>Working capital adjustments</b>		
(Increase) in trade and other receivables	( 2 554)	( 2 511)
(Increase) / Decrease in financial assets	( 6 156)	( 866)
(Increase) / Decrease in inventories	( 1 837)	526
(Increase) in other assets	( 2 309)	( 2 029)
(Decrease) / Increase in trade and other payables	( 11 549)	20 695
(Decrease) / Increase in provisions	( 156)	737
<b>Cash generated from operations</b>	<b>74 875</b>	<b>1 05 531</b>
Income taxes paid	( 27 822)	( 22 954)
<b>Net cash generated from operating activities</b>	<b>47 053</b>	<b>82 577</b>
<b>B. Cash Flows from Investing Activities</b>		
Loan given to related parties	( 70 000)	---
Loan repaid by related parties	70 000	---
Interest received	4 433	3 451
Payment to acquire property, plant and equipment	( 4 468)	( 4 444)
Proceeds from sale of property, plant and equipment	141	2
Changes in earmarked balances	---	---
<b>Net cash generated (used in) investing activities</b>	<b>106</b>	<b>( 991)</b>
<b>C. Cash Flows from Financing Activities</b>		
Dividend paid	( 86 021)	( 47 068)
Principal payment of lease liabilities	( 95)	( 107)
Interest paid on lease liabilities	( 8)	( 12)
Interest paid other than on lease liabilities	( 51)	( 514)
<b>Net cash (used in) financing activities</b>	<b>( 86 175)</b>	<b>( 47 701)</b>
<b>Net (decrease) / increase in cash and cash equivalents</b>	<b>( 39 017)</b>	<b>33 885</b>
Cash and cash equivalents at the beginning of the year	96 383	62 498
Effect of exchange differences on translation of foreign currency cash and cash equivalents	---	7
<b>Cash and cash equivalents at the end of the period / year</b>	<b>57 367</b>	<b>96 383</b>

- The above audited financial results for the quarter and year ended June 30, 2024, have been reviewed and recommended by the Audit Committee, and approved by the Board of Directors of the Company at their respective meetings held on August 28, 2024. These financial results have been subject to an audit by the statutory auditors of the Company, who have expressed an unmodified opinion thereon. These financial results are prepared and published in accordance with Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
- The Financial Results are prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standards (Ind AS), as amended, prescribed under Section 133 of the Companies Act, 2013, read with relevant Rules issued thereunder and other accounting principles generally accepted in India.
- The Board of Directors at its meeting held on August 28, 2024 have recommended a payment of final dividend of ₹ 95 per equity share of face value ₹10 each aggregating to ₹ 30 838 lakhs.
- The Company has arrived at an Advanced Pricing Agreement with the concerned tax authorities, determining appropriate transfer pricing methodology for certain identified transactions with the Company's affiliate(s) for the financial years 2010-11 to 2018-19. As a consequence of this agreement, an additional tax liability, amounting to ₹ 1 656 lakh, and interest amounting to ₹ 1 944 lakhs, have been accounted as Prior Period Tax Adjustments and Finance Costs respectively. In view of the above, contingent liabilities have been reduced by ₹ 8 699 lakhs.
- Certain Property, Plant & Equipment of the Company having a written down value of ₹ 2 282 lakhs as at 30 June, 2024, which were licensed to a contract manufacturer whose arrangement was terminated in F.Y. 2022-23, have been tested for impairment and a loss amounting to ₹ 1303 lakhs has been recognized in the financial results for the quarter and year ended June 30, 2024.
- During the preceding year, the Company had reversed tax provisions amounting to ₹ 5 844 lakhs in respect of past Income Tax Litigations pertaining to certain years, based on a favourable ruling by the Income Tax Appellate Tribunal in a similar case of the Company pertaining to an earlier year.
- The Company has identified Health and Hygiene Products as its single primary reportable segment in accordance with the requirements of Ind AS 108 - Operating Segments. Accordingly, no separate segment information has been provided.
- The Statement of Assets and Liabilities as at June 30, 2024, is attached therewith as Note 1.
- The Statement of Cash Flows for the year ended June 30, 2024, has been prepared under the indirect method as set out in Ind AS-7 on the "Statement of Cash Flows" and is attached herewith as Note 2.
- The figures of last quarter ended June 30 are the balancing figures between audited figures in respect of the full financial year and the published year to date figures up to the third quarter of the respective financial years.

For and on behalf of the Board of Directors of  
Procter & Gamble Hygiene and Health Care Limited

KUMAR  
VENKATASU  
BRAMANIAN  
Kumar Venkatasubramanian  
Managing Director

Digitally signed by KUMAR  
VENKATASUBRAMANIAN  
Date: 2024.08.28 15:10:37  
+05'30'

Place: Mumbai  
Date: 28th August 2024

ROSHNI  
RAYOMAND  
MARFATIA

Digitally signed by ROSHNI RAYOMAND MARFATIA  
DN: cn=ROSHNI RAYOMAND MARFATIA, o=Procter & Gamble Hygiene and Health Care Limited, email=roshni.rayomand.marfatia@pg-hc.com, c=IN  
Date: 2024.08.28 15:10:37 +05'30'